Clinical Trials

Testing a Combination for Metastatic Pancreatic Cancer

A clinical trial tests an investigational drug, immunotherapy, and radiation in combination against advanced pancreatic cancer.

Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.

A clinical trial for at-risk people is looking for biomarkers that can indicate pancreatic cancer is growing.

CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.

A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.

A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.

Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?

An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.

Researchers are using IORT–intraoperative radiation therapy–to treat pancreatic cancer that cannot be surgically removed.

Is chemotherapy before and after pancreatic cancer surgery more effective than just chemotherapy after surgery?